- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 87,850 | 21.06.24 16:05:39 | -0,280 | -0,32% | 87,780 | 87,840 | 87,920 | 88,130 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 987,600 | 21.06.24 15:58:34 | +19,200 | +1,98% | 980,400 | 986,800 | 968,800 | 968,400 |
